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Abstract: Two classes of fused nitrogen heterocycles were designed as CK2 inhibitor candidates on 
the basis of previous structure–activity relationship (SAR) studies. Various 
dipyrrolo[3,2-b:2',3'-e]pyridine and benzo[g]indazole derivatives were prepared using 
transition-metal-catalysed cascade and/or multicomponent reactions. Biological evaluation of these 
candidates revealed that benzo[g]indazole is a promising scaffold for potent CK2 inhibitors. The 
inhibitory activities on cell proliferation of these potent CK2 inhibitors are also presented. 
 
Introduction 
The protein kinase CK2 (previously called casein kinase II) is a ubiquitous and highly 
pleiotropic serine/threonine kinase for more than 300 protein substrates. A number of reports have 
suggested that CK2 is a potential target for cancer treatment because CK2 is overexpressed in a wide 
variety of tumours,1 and various small-molecule CK2 inhibitors have been developed.2 CK2 
predominantly forms a heterotetramer composed of two catalytic subunits (CK2 and/or CK2') and 
two regulatory subunits (CK2).3 The majority of reported small-molecule CK2 inhibitors target the 
ATP-binding site of the catalytic subunits. A benzonaphthyridine derivative CX-4945 (1) has been 
reported as a potent ATP-competitive CK2 inhibitor, and is currently undergoing clinical trials for 
cancer treatment (Figure 1).4 
We have also carried out structure–activity relationship (SAR) studies5 and crystallographic 
analyses6 of pyrazine-based CK2 inhibitors 25b (Figure 1) to obtain structural information for the 
design of novel CK2 inhibitors. These inhibitors 2 bind to CK2 with a planar horseshoe-shaped 
conformation to support favourable interactions via van der Waals contacts with hydrophobic 
residues (Leu45, Val53, Val66, Ile95, Phe113, His160, Met163, and Ile174) in CK2 as well as 
hydrogen bonds with the surrounding residues. A nitrogen atom at the 4-position of a pyrazine ring 
interacts with the backbone NH group of Val116 in the hinge region. The carboxyl group, which is 
necessary for binding to CK2, interacts by a salt bridge and hydrogen bonds with the Lys68 -amino 
group and the backbone NH group of Asp175 in the activation loop, and a water molecule in the 
active site. 
We recently identified 2-phenyl-1,3,4-thiadiazoles 3 and 3-phenyl-1,2-pyrazole derivatives 4 as 
CK2 inhibitor led by virtual screening of a compound library (Figure 1).7 Binding mode analysis of 
the thiadiazole-type inhibitor 3a suggested that unfavourable repulsion exists between one of the 
thiadiazole nitrogen atoms and the backbone oxygen atom of CK2-Glu114 (Figure 2A). The 
pyrazole analogue 4 designed by replacement of the thiadiazole ring in 3b [IC50 = 3.4 M (CK2 
and 1.2 M (CK2' with a pyrazole ring would improve the CK2-binding affinity because the NH 
group of the pyrazole could form an additional hydrogen bond with the Glu114 carbonyl oxygen 
(Figure 2B). The pyrazole-type inhibitor 4 showed more potent inhibitory activity toward CK2 [IC50 
= 0.14 M (CK2 and 0.063 M (CK2' than the thiadiazole 3b did. Because the other tautomer, 
4', may have unfavourable electrostatic repulsions with the binding region (Figure 2B), stabilization 
of tautomer 4 would enhance the inhibitory activity. In this study, we have designed and synthesized 
two classes of fused nitrogen heterocycles, using copper- or gold-catalysed cascade reactions. The in 
vitro inhibitory activities toward two subtypes of the CK2 catalytic subunit (CK2 and CK2') and 
anti-proliferative activity of the potent inhibitors are also presented. 
 
Results and discussion 
Design 
On the basis of our previous SAR studies, we designed two fused nitrogen heterocycles 5 and 6 
as novel CK2 inhibitor candidates (Figure 3). The highly fused and rigid scaffold would fix the 
preferred planar conformation and decrease the entropic loss when incorporated into the binding 
pocket.6 In the dipyrrolo[3,2-b:2',3'-e]pyridine derivative 5, a nitrogen atom of the pyridine core and 
a carboxyl group would form favourable electrostatic interactions with CK2, as the pyrazine-based 
CK2 inhibitors 2 do (Figure 3A).5a,6 The benzo[g]indazole derivatives 6 also have a highly fused and 
planar structure (Figure 3B). More importantly, in the benzo[g]indazole scaffold (a bridged analogue 
of the phenylpyrazole 4) the desired tautomer of the pyrazole moiety would be preferred because of 
the fused benzene ring.8 The stabilization effect of this tautomer in 6 would enhance the chance of 
the NH group forming favourable interactions with the Glu114 carbonyl oxygen. Preliminary 
molecular modelling studies of 6a (R1 = Ph, R2 = H) using the CK2–3a co-crystal structure 
suggested that the carboxyl group and two indazole nitrogens could form favourable interactions 
with CK2 (Figure 3C).  
 
Synthesis 
We expected that the inhibitor candidates 5 and 6 could be synthesized using the 
transition-metal-catalysed cascade reactions which have been developed by us in recent years.9 The 
synthetic route to dipyrrolo[3,2-b:2',3'-e]pyridine derivatives 5a–e is shown in Scheme 1. The 
dipyrrolo[3,2-b:2',3'-e]pyridine framework was constructed using copper-catalysed bis-cyclization of 
2,6-diethynylpyridine-3,5-diamine 7.9a The reaction proceeded smoothly to give 
1,7-bismesyldipyrrolo[3,2-b:2',3'-e]pyridine (8). One of the mesyl groups of 8 was selectively 
removed using Cs2CO3 and methanol to afford 9. The copper-catalysed Ullmann-type coupling of 910 
with several aryl or heteroaryl carboxylic acid esters, followed by successive deprotection of a mesyl 
group and an ester, yielded 1-aryldipyrrolo[3,2-b:2',3'-e]pyridines 5a–e. 
Benzo[g]indazole derivatives 6a–f were prepared via a gold-catalysed three-component 
annulation and cyclization cascade9b as a key step (Scheme 2). 4-Amino-3-bromobenzoic acid (12) 
was converted to the methyl ester 13 under acidic conditions. A Sandmeyer reaction using potassium 
iodide, followed by a Sonogashira coupling with trimethylsilylacetylene (TMS-acetylene) afforded 
the common intermediate 15. A second Sonogashira coupling with several acetylenes, using 
tri-tert-butylphosphine as a ligand for palladium,11 and removal of the TMS group gave methyl 
3,4-diethynylbenzoates 17a–d. A three-component annulation and cyclization cascade of 17 with a 
hydrazine derivative 18 and aldehydes 19, using a catalytic amount of IPrAuCl [IPr = 
1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene] and AgOTf, afforded the desired 
2,3-dihydrobenzo[g]indazole derivatives 20a–f. The cleavage of a 4-methoxybenzyl (PMB) group 
and aromatization of a dihydropyrazole ring were achieved by treatment with 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) or trifluoroacetic acid (TFA) to give the 
benzo[g]indazoles 21a–f. Finally, full deprotection of the methyl carbamate and ester yielded the 
desired compounds 6a–f. 
 The 3,4-unsubstituted congener 6g (R1 and R2 = H) was prepared via a different synthetic 
route (Scheme 3), because of difficulties in using 17 bearing two terminal alkynes (R1 = H) for the 
three-component annulation. The 5-aryl-1-benzylpyrazole derivative 26 was prepared according to 
the traditional method for construction of pyrazoles from the acetophenone derivative 22. A 
Sonogashira coupling of 26 with TMS-acetylene, followed by removal of a TMS group, afforded the 
cyclization precursor 27. The alkyne 27 was heated with a catalytic amount of IPrAuCl and silver 
bis(trifluoromethanesulfonyl)imide (AgNTf2) to give a benzo[g]indazole derivative 21g via 
intramolecular hydroarylation of an alkyne, based on our three-component annulation and cyclization 
cascade. The entire deprotection of the benzyl group12 and methyl ester yielded the desired 
compound 6g. 
 
Evaluation of CK2 inhibitory activity 
The inhibitory activities of the synthesized analogues toward two subtypes of the catalytic 
subunit of CK2 (CK2 and CK2') are summarised in Table 1. Although the 
dipyrrolo[3,2-b:2',3'-e]pyridine derivative bearing a benzoic acid, 5a, had significantly less potent 
activity, its pyridine congener 5b showed moderate activity toward both CK2 and CK2' (IC50 = 41 
M and 26 M, respectively). The position of the carboxyl group also had a distinct effect on the 
activity: the analogue bearing a 4-carboxypyridine moiety, 5c, exhibited higher activity toward 
CK2 (IC50 = 14 M) and CK2' (IC50 = 12 M) than did the 3-, 5-, and 2-substituted analogues 5b, 
5d, and 5e. 
In contrast, benzo[g]indazole derivatives gave more promising results. The 
4-methoxybenzene-substituted analogue 6b and the thiophene-substituted one 6d were more potent 
than the parent pyrazole derivative 4, despite the loss of the amino group on the pyrazole ring of 4, 
which would form a favourable hydrogen bond with the Val116 carbonyl oxygen (Figure 2B). These 
results suggest that the benzo[g]indazole core would be a more suitable scaffold for potent CK2 
inhibitors than the biaryl-type pyrazoles would be, presumably because of the rigidity of the 
molecule and/or the predominance of the preferable tautomer of the pyrazole ring. The introduction 
of an isopropyl group as R2 reduced the binding affinity 100-fold relative to those of the 
unsubstituted analogues (compare 6b with 6c, and 6d with 6e). On the other hand, the absence of a 
substituent at the 4-position (R1 = H, 6g) also lowered the activity relative to those of the other 
4-substituted analogues. An aromatic group was preferable to an alkyl chain as the substituent R1, 
and the electrostatic and/or steric environment of the aromatic ring slightly affected the binding 
affinity. These observations correspond with the predicted binding affinities of –23.8, –22.0, and 
–20.7 kcal/mol for 6a, 6f, and 6g, respectively. 
 
Evaluation of cytotoxic activity 
Compounds 4, 6b, and 6d, which exerted potent CK2 inhibitory activities, were tested for 
anti-proliferative effects on colorectal cancer cells, HCT-116 (Figure 4). The cancer cells were 
treated with increasing concentrations of the compounds, and viabilities were measured by the 
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay. The pyrazole 4 had a lower than 50% inhibitory effect at 100 M, whereas the 
benzo[g]indazoles 6b and 6d exhibited moderate inhibitory effects (IC50 = 26.5 M and 21.0 M, 
respectively), slightly lower than that of 1 (IC50 = 6.7 M). These data are in linear correlation with 
the CK2 inhibitory effects. 
 
Conclusion 
In conclusion, we have designed dipyrrolo[3,2-b:2',3'-e]pyridine and benzo[g]indazole 
derivatives as novel CK2 inhibitor candidates, based on our previous SAR studies. A series of 
benzo[g]indazole analogues were efficiently prepared using our three-component cascade reaction. 
Evaluation of the resulting derivatives for CK2 inhibitory activities led to identification of novel 
potent inhibitors such as the thiophene-substituted benzo[g]indazole derivative 6d. Benzo[g]indazole 
is a promising scaffold for highly potent CK2 inhibitors. These results will provide useful 
information for further studies on CK2 inhibitors with high selectivity toward the two isozymes 




Melting points were measured by a hot stage melting point apparatus (uncorrected). 1H NMR 
spectra were recorded using a JEOL AL-400 or JEOL ECA-500 spectrometer, and chemical shifts are 
reported in  (ppm) relative to TMS as internal standard. 13C NMR spectra were recorded using a 
JEOL AL-400 or JEOL ECA-500 spectrometer and referenced to the residual solvent signal. 1H 
NMR spectra are tabulated as follows: chemical shift, number of protons, multiplicity (b = broad, s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and coupling constant(s). Exact mass 
(HRMS) spectra were recorded on a JMS-HX/HX 110A mass spectrometer. Infrared (IR) spectra 
were obtained on a JASCO FT/IR-4100 FT-IR spectrometer with JASCO ATR PRO410-S. 
Compounds 7,9a 8,9a and 2213 were prepared according to the literatures. 
 
1-(Methylsulfonyl)-1,7-dihydrodipyrrolo[3,2-b:2',3'-e]pyridine (9). To the mixture of 8 
(700 mg, 2.23 mmol) in MeOH/THF (1:1, 220 cm3) was added Cs2CO3 (2.18 g, 6.70 mmol). After 
stirring at rt for 12 h, NH4Cl (835 mg, 15.6 mmol) was added and the mixture was stirred at rt for 1.5 
h. It was concentrated in vacuo and the residue was diluted with CHCl3. After filtration, the mixture 
was concentrated and the residue was chromatographed on silica gel (CHCl3/MeOH = 10/1) to afford 
the title compound 9 (407 mg, 78%) as a white solid: mp 218–219 °C (decomp); δH (400 MHz; 
CDCl3; Me4Si) 3.05 (3H, s), 6.80–6.82 (1H, m), 6.97 (1H, dd, J 3.8, 0.6 Hz), 7.57–7.59 (1H, m), 
7.65 (1H, d, J 3.8 Hz), 8.25 (1H, br s), and 8.46 (1H, s); δC (100 MHz; CDCl3) 40.2, 103.1, 103.1, 
110.7, 127.0, 128.8, 129.5, 131.3, 145.4, and 145.7. Anal. Found: C, 52.0; H, 3.9; N, 17.9. Calc. for 
C10H9N3O2S: C, 52.0; H, 3.8; N, 17.6%. 
 
Representative procedure for coupling reactions of 9 with aryl halides 10a–e: synthesis of 
ethyl 4-{7-(Methylsulfonyl)dipyrrolo[3,2-b:2',3'-e]pyridin-1(7H)-yl}benzoate (11a). Under argon 
atmosphere, the mixture of 9 (50 mg, 0.21 mmol), ethyl 4-iodobenzoate (10a) (70 mg, 0.26 mmol), 
CuI (4 mg, 0.021 mmol), (±)-trans-N,N'-dimethylcyclohexane-1,2-diamine A (0.007 cm3, 0.042 
mmol), and K3PO4 (113 mg, 0.53 mmol) in 1,4-dioxane (1 cm3) was refluxed for 3 h. The mixture 
was diluted with EtOAc and filtered. The filtrate was concentrated and chromatographed on silica gel 
(hexane/EtOAc = 1/1) to afford the title compound 11a (73 mg, 90%) as a white solid: mp 75–76 °C; 
IR (neat): max/cm-1 1698 (C=O), 1278 (OCH3); δH (400 MHz; CDCl3; Me4Si) 1.44 (3H, t, J 7.1 Hz), 
3.06 (3H, s), 4.43 (2H, q, J 7.1 Hz), 6.96 (1H, d, J 3.7 Hz), 6.98 (1H, d, J 3.7 Hz), 7.58–7.61 (2H, m), 
7.68 (1H, d, J 3.7 Hz), 7.72 (1H, d, J 3.7 Hz), 8.24–8.27 (2H, m), and 8.40 (1H, s); δC (100 MHz; 
CDCl3) 14.3, 40.4, 61.2, 102.5, 105.0, 110.3, 123.1 (2C), 126.0, 127.0, 128.7, 129.4, 131.5 (2C), 
132.1, 142.6, 145.8, 146.9, and 165.6; HRMS (FAB) m/z Calc. for C19H18N3O4S (MH+) 384.1013, 
found 384.1014. 
 
Representative procedure for removal of protecting groups of 11a–e: Synthesis of 
4-{dipyrrolo[3,2-b:2',3'-e]pyridin-1(7H)-yl}benzoic acid (5a). To the mixture of 11a (60 mg, 0.16 
mmol) in MeOH/THF (1:1, 16 cm3) was added Cs2CO3 (153 mg, 0.47 mmol). After stirring at rt for 
12 h, the mixture was concentrated in vacuo. The residue was diluted with sat. aqueous NH4Cl and 
the mixture was extracted with EtOAc twice. The combined extracts were washed with brine, dried 
over Na2SO4, and concentrated in vacuo. The crude product was dissolved with THF (3 cm3) and 3N 
NaOH (0.3 cm3) was added. The mixture was stirred at rt for 40 h and concentrated in vacuo. The 
residue was dissolved in water (ca. 1 cm3) and filtered. The filtrate was acidified with 3N HCl, then 
28% aqueous NH3 was added until the mixture was clear solution. The solution was freeze dried and 
the residue was purified by reverse phase HPLC [3–6% MeCN in H2O (containing 0.1% NH3); flow 
rate: 10 cm3 min-1] to afford the title compound 5a as an NH3 salt (24.9 mg, 54%). Pale yellow solid: 
mp >300 °C; IR (neat):max/cm-1 1602 (C=O); δH (500 MHz; DMSO-d6; Me4Si) 6.55–6.57 (1H, br 
m), 6.82 (1H, d, J 3.4 Hz), 7.65–7.67 (1H, m), 7.81 (2H, d, J 8.0 Hz), 7.98 (1H, d, J 3.4 Hz), 8.05 
(1H, s), 8.16 (2H, d, J 8.0 Hz), and 11.03 (1H, s); δC (125 MHz; DMSO-d6) 99.7, 100.4, 104.5, 122.3 
(2C), 125.5, 126.6, 128.0, 129.6, 130.5, 131.1 (2C), 142.8, 144.3, 144.4, and 166.8; HRMS (FAB) 
m/z Calc. for C16H10N3O2 [M – H]– 276.0779, found 276.0781. 
 
Methyl 4-amino-3-bromobenzoate (13). To the mixture of 4-amino-3-bromobenzoic acid 12 
(5.4 g, 25 mmol) in MeOH (30 cm3) was added sulphuric acid (0.83 cm3), then the mixture was 
refluxed for 20 h. The mixture was cooled to 0 °C and basified with sat. aqueous NaHCO3 (ca. 100 
cm3). The precipitates were collected and washed with water. Recrystallization from MeOH-H2O 
afforded the title compound 13 (5.34 g, 93%) as a white solid. All spectral data were in good 
agreement with those reported by Bräse et al.14 
 
Methyl 3-bromo-4-iodobenzoate (14). To the stirred suspension of 13 (5.0 g, 21.7 mmol) in 
6N HCl (40 cm3) was added a solution of NaNO2 (3.0 g, 43.4 mmol) in H2O (20 cm3) dropwise over 
15 min at 0 °C. After stirring at 0 °C for 1 h, a solution of KI (5.4 g, 32.6 mmol) in H2O (16 cm3) 
was added dropwise to the reaction mixture over 15 min at 0 °C. The mixture was vigorously stirred 
at rt for 24 h in the dark. The precipitate was collected and washed with H2O. The solid was 
dissolved in Et2O, then the mixture was washed with aqueous Na2S2O3, H2O, and brine, dried over 
MgSO4, and concentrated in vacuo. The residue was filtered through a silica gel pad with elution of 
hexane/EtOAc (50/1). The filtrate was concentrated and recrystallized from hot hexane to afford the 
title compound 14 (3.9 g, 53%) as colourless crystals. All spectral data were in good agreement with 
those reported.15 
 
Methyl 3-bromo-4-[(trimethylsilyl)ethynyl]benzoate (15). Under argon atmosphere, Et3N 
(7.3 cm3, 53 mmol) and TMS-acetylene (1.8 cm3, 12.7 mmol) were added to the mixture of 14 (3.6 g, 
10.6 mmol), PdCl2(PPh3)2 (190 mg, 0.27 mmol) and CuI (50 mg, 0.27 mmol) in THF (35 cm3), then 
the mixture was stirred at rt for 12 h. The mixture was concentrated in vacuo and the residue was 
diluted with Et2O and filtered through a silica gel pad. The filtrate was concentrated in vacuo and the 
residue was chromatographed on silica gel (hexane/EtOAc = 20/1) to afford the title compound 15 
(3.19 g, 97%) as a yellow oil. All spectral data were in good agreement with those reported.16 
 
Representative procedure for coupling reactions of 15 with 16a–d and removal of a TMS 
group: Synthesis of methyl 4-ethynyl-3-(thiophen-2-ylethynyl)benzoate (17c). Under argon 
atmosphere, 15 (938 mg, 3.01 mmol) was dissolved in toluene (3 cm3). To the solution were added 
PdCl2(PhCN)2 (35 mg, 0.09 mmol), CuI (11 mg, 0.06 mmol), i-Pr2NH (1.3 cm3, 9.03 mmol), 
2-ethynylthiophene (16c),17 and a solution of t-Bu3P in toluene (1.0 M, 0.18 cm3) and the mixture 
was stirred at rt for 7 h. The resulting mixture was filtered through a silica gel pad with elution of 
hexane/EtOAc (9/1). The filtrate was concentrated in vacuo and chromatographed on silica gel 
(hexane/EtOAc = 9/1) to afford methyl 3-(thiophen-2-ylethynyl)-4-[(trimethylsilyl)ethynyl]benzoate 
(994 mg, 98%) as a yellow solid: mp 71–72 °C; IR (neat):max/cm-1 2210, 2159 (C≡C), 1246 
(OCH3); δH (400 MHz; CDCl3; Me4Si) 0.29 (9H, s), 3.92 (3H, s), 7.03 (1H, dd, J 5.1, 3.7 Hz), 
7.31–7.33 (2H, m), 7.54 (1H, d, J 8.2 Hz), 7.90 (1H, dd, J 8.2, 1.7 Hz), and 8.16 (1H, d, J 1.7 Hz); δC 
(100 MHz; CDCl3) 52.5, 87.5, 91.2, 102.5, 102.6, 123.0, 126.3, 127.3, 128.1, 128.7, 129.5, 129.8, 
132.3, 132.5, 132.7, and 166.0; HRMS (FAB) m/z Calc. for C19H19O2SSi (MH+) 339.0870, found 
339.0874. 
The coupling product (475 mg, 1.40 mmol) was dissolved in MeOH (14 cm3). After addition of 
K2CO3 (388 mg, 2.80 mmol), the mixture was stirred at rt for 1 h. The resulting mixture was 
acidified with sat. aqueous citric acid and extracted with Et2O. The extract was washed with H2O and 
brine, dried over MgSO4, and concentrated in vacuo. The residue was chromatographed on silica gel 
(hexane/EtOAc = 9/1) followed by recrystallization from CHCl3-hexane to afford the title compound 
17c (259 mg, 70%) as pale yellow crystals: mp 75–76 °C; IR (neat):max/cm-1 3246 (C≡CH), 2195 
(C≡C), 1717 (C=O), 1244 (OCH3); δH (500 MHz; CDCl3; Me4Si) 3.51 (1H, s), 3.93 (3H, s), 
7.02–7.04 (1H, m), 7.33 (1H, s), 7.34–7.35 (1H, m), 7.58 (1H, d, J 8.0 Hz), 7.93 (1H, dd, J 8.0, 1.7 
Hz), and 8.18 (1H, d, J 1.7 Hz); δC (125 MHz; CDCl3) 52.4, 81.4, 84.1, 87.6, 90.7, 126.4, 127.2, 
128.1, 128.4, 128.7, 130.1, 132.6, 132.6 (2C), and 165.8. Anal. Found: C, 72.4; H, 4.0. Calc. for 
C16H10O2S: C, 72.2; H, 3.8%.  
 
Methyl 2-(4-methoxybenzyl)hydrazinecarboxylate (18). The mixture of methyl 
hydrazinecarboxylate (10.0 g, 111 mmol) and p-anisaldehyde (15 cm3, 122 mmol) in Et2O (400 cm3) 
was stirred at 35 °C for 15 h. The reaction mixture was concentrated in vacuo until ca. 50 cm3 and 
the residue was diluted with toluene. The precipitate was collected and washed with hexane to afford 
methyl 2-(4-methoxybenzylidene)hydrazinecarboxylate (20.3 g, 88%) as a white solid: mp 
123–124 °C; IR (neat):max/cm-1 3252 (NH), 1712 (C=O), 1249 (OCH3); δH (400 MHz; CDCl3; 
Me4Si) 3.84 (3H, s), 3.85 (3H, br s), 6.90 (2H, d, J 8.8 Hz), 7.63 (2H, d, J 8.8 Hz), 7.79 (1H, br s), 
and 7.90 (1H, s); δC (100 MHz; CDCl3) 52.7, 55.2, 113.9 (2C), 126.4, 128.7 (2C), 144.8, 154.6, and 
161.0. Anal. Found: C, 57.6; H, 5.6; N, 13.6. Calc. for C10H12N2O3: C, 57.7; H, 5.8; N, 13.5%.  
The mixture of benzylidenehydrazine (5.0 g, 24.0 mmol) and 10% Pd/C (2.5 g) in EtOH (340 
cm3) was stirred under hydrogen atmosphere at rt for 1.5 h. The reaction mixture was filtered through 
Celite and concentrated. The residue was chromatographed on silica gel (hexane/EtOAc = 2/3) 
followed by recrystallization from hexane to afford the title compound 18 (3.56 g, 71%) as 
colourless crystals: mp 63–64 °C; IR (neat):max/cm-1 3301 (NH), 1684 (C=O), 1251 (OCH3); δH 
(400 MHz; CDCl3; Me4Si) 3.73 (3H, br s), 3.80 (3H, s), 3.94 (2H, d, J 4.9 Hz), 4.15 (1H, br s), 6.15 
(1H, br s), 6.86–6.88 (2H, m), and 7.25–7.27 (3H, m); δC (100 MHz; CDCl3) 52.3, 55.1, 55.2, 113.8 
(2C), 129.4, 130.1 (2C), 157.8, and 159.0. Anal. Found: C, 57.3; H, 6.5; N, 13.4. Calc. for 
C10H14N2O3: C, 57.1; H, 6.7; N, 13.3%.  
 
Representative procedure for gold-catalysed three-component annulation and cyclisation 
cascade reactions of 17a–d with 18 and 19a,b: Synthesis of dimethyl 
2-(4-methoxybenzyl)-4-(4-methoxyphenyl)-2,3-dihydro-1H-benzo[g]indazole-1,7-dicarboxylate 
(20b). Under argon atmosphere, the mixture of 17b (20 mg, 0.069 mmol), a hydrazine 18 (5.8 mg, 
0.028 mmol), paraformaldehyde 19a (1.7 mg, 0.055 mmol as HCHO), IPrAuCl (2.1 mg, 3.5 mol), 
and AgOTf (0.9 mg, 3.5 mol) in AcOH (0.35 cm3) was stirred at 35 °C for 2 h, then the additional 
hydrazine 18 (5.8 mg, 0.028 mmol) and paraformaldehyde 19a (1.7 mg, 0.055 mmol as HCHO) were 
added. After stirred at 35 °C for 2 h, further hydrazine 18 (5.8 mg, 0.028 mmol) and 
paraformaldehyde 19a (1.7 mg, 0.055 mmol as HCHO) were added and stirred for 2 h. The reaction 
mixture was poured into sat. aqueous NaHCO3 and the mixture was extracted with EtOAc twice. The 
combined extracts were washed with H2O and brine, dried over Na2SO4, and concentrated in vacuo. 
The residue was chromatographed on silica gel (hexane/EtOAc = 10/1 to 2/1) to afford the title 
compound 20b [11.5 mg, 33% (41% rsm)] as a yellow oil: IR (neat):max/cm-1 1716, 1609 (C=O), 
1251 (OCH3); δH (500 MHz; CDCl3; Me4Si, 50 °C) 3.75 (3H, s), 3.79 (2H, br s), 3.79 (3H, s), 3.86 
(3H, s), 3.99 (3H, s), 4.34 (2H, br s), 6.76 (2H, d, J 8.6 Hz), 7.00 (2H, d, J 8.6 Hz), 7.19 (2H, d, J 8.6 
Hz), 7.37 (2H, d, J 8.6 Hz), 7.81 (1H, s), 8.01–8.07 (2H, m), and 8.63 (1H, s); δC (100 MHz; CDCl3) 
52.3, 53.6, 55.2, 55.4, 57.7, 61.7, 113.5 (2C), 114.4 (2C), 124.8, 125.6, 125.8, 127.2, 127.5, 128.3, 
129.2 (2C), 130.1, 131.1 (2C), 131.2, 131.5, 133.6, 136.2, 137.3, 157.0, 159.1, 159.5, and 167.1; 
HRMS (FAB) m/z Calc. for C30H29N2O6 (MH+) 513.2020, found 513.2011. 
 
Dimethyl 3-isopropyl-2-(4-methoxybenzyl)-4-(thiophen-2-yl)-2,3-dihydro-1H-benzo[g]-
indazole-1,7-dicarboxylate (20e). Under argon atmosphere, the mixture of 17c (40 mg, 0.15 mmol), 
a hydrazine 18 (35 mg, 0.17 mmol), isobutyraldehyde 19b (0.027 cm3, 0.30 mmol), IPrAuCl (4.7 mg, 
7.5 mol), and AgOTf (1.9 mg, 7.5 mol) in AcOH (1.5 cm3) was stirred at 50 °C for 7 h. The 
reaction mixture was poured into sat. aqueous NaHCO3 and the mixture was extracted with EtOAc 
twice. The combined extracts were washed with H2O and brine, dried over Na2SO4, and concentrated 
in vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 4/1) to afford the title 
compound 20e (67.6 mg, 85%) as a yellow oil: IR (neat):max/cm-1 1717, 1612 (C=O); δH (400 
MHz; CDCl3; Me4Si) 0.53 (3H, d, J 6.8 Hz), 0.61 (3H, d, J 6.8 Hz), 1.55–1.63 (1H, m), 3.77 (1H, d, 
J 12.2 Hz), 3.79 (3H, s), 3.86 (3H, s), 3.99 (3H, s), 4.12 (1H, d, J 12.2 Hz), 4.36 (1H, d, J 3.4 Hz), 
6.84 (2H, d, J 8.5 Hz), 7.11 (1H, dd, J 4.8, 3.4 Hz), 7.21 (1H, d, J 3.7 Hz), 7.34–7.38 (3H, m), 7.90 
(1H, s), 8.00–8.07 (2H, m), and 8.61 (1H, s); δC (100 MHz; CDCl3) 16.0, 20.1, 30.9, 52.2, 53.3, 55.2, 
62.6, 72.4, 113.4 (s, 2H), 124.9, 125.5, 125.7, 125.9, 126.0, 127.6, 127.7, 127.8, 128.5, 129.6, 131.1, 
131.2, 131.6 (s, 2H), 133.6, 137.6, 141.3, 157.1, 159.2, and 167.0; HRMS (FAB) m/z Calc. for 
C30H31N2O5S (MH+) 531.1948, found 531.1946. 
 
Deprotection and aromatisation of 20: 4-Phenyl-1H-benzo[g]indazole-7-carboxylic acid 
(6a). Compound 20a (20 mg, 0.042 mmol) and anisole (0.022 cm3, 0.21 mmol) were dissolved in 
TFA (0.6 cm3). After stirring at 80 °C for 12 h, the mixture was poured into sat. aqueous NaHCO3 
and the mixture was extracted with EtOAc twice. The combined extracts were washed with H2O and 
brine, dried over Na2SO4, and concentrated in vacuo. The crude product (21a) was dissolved in 
1,4-dioxane (0.4 cm3), then 3N NaOH (0.083 cm3, 0.25 mmol) was added. After stirring at 40 °C for 
12 h, NH4Cl (22 mg, 0.42 mmol) was added and the mixture was stirred at rt for 1 h. The mixture 
was concentrated in vacuo and the residue was chromatographed on silica gel (CHCl3/MeOH = 9/1) 
to afford the title compound 6a (5.8 mg, 49%) as a white solid: mp >300 °C; IR (neat):max/cm-1 
1703 (C=O); δH (500 MHz; DMSO-d6; Me4Si) 7.48 (1H, dd, J 7.6, 7.6 Hz), 7.58 (2H, dd, J 7.6, 7.6 
Hz), 7.78 (1H, s), 7.85 (2H, d, J 7.6 Hz), 8.17 (1H, d, J 8.6 Hz), 8.28 (1H, s), 8.53 (1H, d, J 8.6 Hz), 
and 8.70 (1H, s); δC (125 MHz; DMSO-d6) 118.7, 121.0, 121.6 (2C), 123.3, 126.49, 126.53, 127.9, 
128.2 (2C), 129.0 (2C), 130.4, 131.4, 131.7, 133.0, 139.1, and 167.8; HRMS (FAB) m/z Calc. for 
C18H11N2O2 [M – H]– 287.0826, found 287.0820.  
 
3-Isopropyl-4-(thiophen-2-yl)-1H-benzo[g]indazole-7-carboxylic acid (6e). The mixture of 
20e (65 mg, 0.12 mmol) and DDQ (83 mg, 0.37 mmol) in CH2Cl2/H2O (5/1, 1.2 cm3) was stirred at 
rt for 18 h. The resulting mixture was diluted with CHCl3, washed with H2O, and dried over Na2SO4. 
The solvent was removed in vacuo and the residue was chromatographed on silica gel (CHCl3) to 
afford the title compound 21e (36.8 mg, 73%) as a white solid: mp 135–136 °C; IR (neat):max/cm-1 
1746, 1714 (C=O), 1262 (OCH3); δH (500 MHz; CDCl3; Me4Si) 1.21 (6H, d, J 6.9 Hz), 2.99–3.04 
(1H, m), 4.00 (3H, s), 4.20 (3H, s), 7.14–7.16 (2H, m), 7.45 (1H, d, J 4.6 Hz), 7.79 (1H, s), 8.20 (1H, 
dd, J 8.6, 1.7 Hz), 8.65 (1H, s), and 9.11 (1H, d, J 8.6 Hz); δC (125 MHz; CDCl3) 22.0 (2C), 27.1, 
52.3, 55.2, 123.1, 123.5, 125.9, 126.1, 126.3, 126.8, 126.9, 128.0, 128.5, 130.1, 131.1, 132.7, 138.8, 
139.5, 152.5, 157.8, and 166.7; HRMS (FAB) m/z Calc. for C22H21N2O4S (MH+) 409.1217, found 
409.1215. 
The mixture of 21e (30 mg, 0.073 mmol) and 3N NaOH (15 cm3, 0.44 mmol) in 1,4-dioxane 
was stirred at 40 °C for 12 h. After addition of NH4Cl (39 mg, 0.73 mmol), the mixture was stirred at 
rt for 1 h, then concentrated in vacuo. The residue was chromatographed on silica gel (CHCl3/MeOH 
= 9/1) to afford the title compound 6e (19.9 mg, 81%) as a white solid: mp >300 °C; IR 
(neat):max/cm-1 1681 (C=O); δH (500 MHz; DMSO-d6; Me4Si) 1.15 (6H, d, J 6.9 Hz), 3.09–3.14 
(1H, m), 7.23 (1H, dd, J 4.9, 3.7 Hz), 7.31 (1H, d, J 3.7 Hz), 7.62 (1H, s), 7.70 (1H, d, J 4.9 Hz), 
8.17 (1H, d, J 8.6 Hz), 8.56 (1H, d, J 8.6 Hz), and 8.67 (1H, s); δC (125 MHz; DMSO-d6) 22.7 (2C), 
26.3, 116.0, 121.9, 122.9, 124.0, 126.3 (2C), 127.3, 127.45, 127.51, 128.7, 130.4, 130.6, 138.9, 140.3, 
150.3, and 167.3; HRMS (FAB) m/z Calc. for C19H15N2O2S [M – H]– 335.0860, found 335.0865. 
 
Methyl 3-bromo-4-[3-(dimethylamino)acryloyl]benzoate (24). The mixture of 22 (5.53 g, 
21.5 mmol) in dimethylformamide dimethylacetal (23) (17.3 cm3, 129 mmol) was stirred at 85 °C for 
8 h in an open vessel. After cooled to rt, the reaction mixture was concentrated in vacuo and the 
residue was recrystallized from EtOAc-Et2O to afford the title compound 24 (5.77 g, 86%) as yellow 
crystals: mp 102–103 °C; IR (neat):max/cm-1 1719 (C=O), 1640 (C=O); δH (500 MHz; CDCl3; 
Me4Si) 2.90 (4H, s), 3.11 (3H, br s), 3.93 (3H, s), 5.30 (1H, d, J 12.6 Hz), 6.74 (1H, br s), 7.40 (1H, 
br s), 7.97 (1H, dd, J 8.0, 1.7 Hz), and 8.24 (1H, d, J 1.7 Hz); δC (125 MHz; CDCl3) 37.2, 45.1, 52.4, 
95.0, 98.7, 128.2, 128.4, 129.3, 131.4, 134.1, 154.1, 157.2, and 165.4. Anal. Found: C, 50.3; H, 4.4; 
N, 4.5. Calc. for C13H14BrN2O3: C, 50.0; H, 4.5; N, 4.5%.  
 
Methyl 4-(1-benzyl-1H-pyrazol-5-yl)-3-bromobenzoate (26). The mixture of 24 (312 mg, 
1.0 mmol), BnNHNH2 (25) (0.22 cm3, 2.0 mmol), and AcONa (205 mg, 2.5 mmol) in AcOH (1.0 
cm3) was stirred at 60 °C for 5 h. The mixture was diluted with H2O and cooled on ice. To the 
mixture was added NaOH until the pH was about 12, then the resulting mixture was extracted with 
Et2O twice. The combined extracts were washed with 1N HCl, H2O, and brine, dried over Na2SO4, 
and concentrated in vacuo. The residue was chromatographed on silica gel (hexane/EtOAc = 4/1) to 
afford the title compound 26 (248 mg, 67%) as a colourless oil: IR (neat):max/cm-1 1725 (C=O), 
1283 (OCH3); δH (400 MHz; CDCl3; Me4Si) 3.95 (3H, s), 5.19 (2H, s), 6.35 (1H, d, J 1.7 Hz), 
6.92–6.94 (2H, m), 7.18–7.21 (4H, m), 7.63 (1H, d, J 1.7 Hz), 7.92 (1H, dd, J 7.9, 1.7 Hz), and 8.33 
(1H, d, J 1.7 Hz); δC (125 MHz; CDCl3) 52.5, 53.8, 107.7, 124.4, 127.1, 127.6 (2C), 128.0, 128.4 
(2C), 132.1, 133.8, 133.8, 136.4, 136.5, 138.8, 140.8, and 165.1; HRMS (FAB) m/z Calc. for 
C18H16BrN2O2 (MH+) 371.0390, found 371.0383. 
 
Methyl 4-(1-benzyl-1H-pyrazol-5-yl)-3-ethynylbenzoate (27). To the mixture of 26 (74 mg, 
0.20 mmol), PdCl2(PhCN)2 (7.7 mg, 0.020 mmol), CuI (3.8 mg, 0.020 mmol) in toluene (0.5 cm3) 
were added i-Pr2NH (0.084 cm3, 0.60 mmol) and TMS-acetylene (0.055 cm3, 0.40 mmol), and a 
solution of t-Bu3P in toluene (1.0 M, 0.040 cm3) under argon atmosphere. After stirring at 20 °C for 
4.5 h, the mixture was diluted with Et2O. The resulting mixture was washed with H2O and brine, 
dried over Na2SO4, and concentrated in vacuo. The residue was chromatographed on silica gel 
(hexane/EtOAc = 4/1) to afford methyl 
4-(1-benzyl-1H-pyrazol-5-yl)-3-[(trimethylsilyl)ethynyl]benzoate (73 mg, containing inseparable 
impurities, <94%) as a yellow oil. This crude product was used for the next reaction without further 
purifications. δH (400 MHz; CDCl3; Me4Si) 0.16 (9H, s), 3.94 (3H, s), 5.27 (2H, s), 6.40 (1H, d, J 2.0 
Hz), 6.91–6.93 (2H, m), 7.18–7.24 (4H, m), 7.60 (1H, d, J 1.7 Hz), 7.92 (1H, dd, J 8.0, 1.7 Hz), and 
8.21 (1H, d, J 1.7 Hz). 
The coupling product (73 mg) was dissolved in MeOH (2.0 cm3). After addition of K2CO3 (52 
mg, 0.38 mmol), the mixture was stirred at rt for 1 h, then diluted with H2O and extracted with 
EtOAc. The extract was washed with brine, dried over Na2SO4, and concentrated in vacuo. The 
residue was chromatographed on silica gel (hexane/EtOAc = 4/1 to 2/3) to afford the title compound 
27 (29.1 mg, 46%) as a yellow oil: IR (neat):max/cm-1 3289 (C≡CH), 1726 (C=O), 1295 (OCH3); δH 
(400 MHz; CDCl3; Me4Si) 3.13 (1H, s), 3.94 (3H, s), 5.28 (2H, s), 6.42 (1H, d, J 2.0 Hz), 6.92–6.94 
(2H, m), 7.18–7.26 (4H, m), 7.62 (1H, d, J 2.0 Hz), 7.96 (1H, dd, J 8.0, 2.0 Hz), and 8.26 (1H, d, J 
1.7 Hz); δC (100 MHz; CDCl3) 52.4, 53.9, 80.7, 82.1, 107.9, 122.9, 127.1 (2C), 127.5, 128.5 (2C), 
129.5, 130.6, 130.7, 134.4, 137.0, 137.8, 139.0, 140.7, and 165.7; HRMS (FAB) m/z Calc. for 
C20H17N2O2 (MH+) 317.1285, found 317.1290. 
 
Methyl 1-benzyl-1H-benzo[g]indazole-7-carboxylate (21g). Under argon atmosphere, the 
mixture of 27 (29 mg, 0,092 mmol), IPrAuCl (2.9 mg, 4.6 mol), and AgNTf2 (1.8 mg, 4.6 mol) in 
xylene was stirred at 130 °C for 4 h. The resulting mixture was filtered and concentrated in vacuo. 
The residue was chromatographed on silica gel (hexane/EtOAc = 4/1) to afford the title compound 
21g (11.0 mg, 38%) as a white solid: mp 163–164 °C; IR (neat):max/cm-1 1715 (C=O), 1284 
(OCH3); δH (500 MHz; CDCl3; Me4Si) 3.96 (3H, s), 6.11 (2H, s), 7.09 (2H, d, J 7.4 Hz), 7.23–7.30 
(3H, m), 7.60 (1H, d, J 9.2 Hz), 7.78 (1H, d, J 9.2 Hz), 8.05 (1H, dd, J 8.6, 1.7 Hz), 8.18 (1H, s), 
8.20 (1H, s), and 8.65 (1H, d, J 1.7 Hz); δC (125 MHz; CDCl3) 52.2, 56.3, 120.2, 122.1, 123.1, 123.6, 
125.8, 126.1, 127.2, 128.8, 131.4, 131.5, 132.6, 133.9 (2C), 134.2 (2C), 135.3, 136.6, and 166.9; 
HRMS (FAB) m/z Calc. for C20H17N2O2 (MH+) 317.1285, found 317.1290. 
 
1H-Benzo[g]indazole-7-carboxylic acid (6g). Under oxygen atmosphere, 21g (11 mg, 0.035 
mmol) and DMSO (0.025 cm3, 0.35 mmol) were dissolved in THF (0.35 cm3) and the mixture was 
cooled to 0 °C. To the mixture was added t-BuOK (27 mg, 0.24 mmol) and the resulting mixture was 
stirred for 15 min. After addition of H2O (0.1 cm3), the mixture was stirred at 0 °C for 0.5 h and at rt 
for 0.5 h. The mixture was diluted with H2O (ca. 0.5 cm3) and NH4Cl (28 mg, 0.52 mmol) was added 
to it. After stirring at rt for 1 h, the mixture was freeze dried and the residue was purified by reverse 
phase HPLC [3–6% MeCN in H2O (containing 0.1% NH3); flow rate: 10 cm3 min-1] to afford the 
title compound 6g as an NH3 salt (3.3 mg, 41%). White solid: mp >300 °C; IR (neat):max/cm-1 1689 
(C=O); δH (400 MHz; DMSO-d6; Me4Si) 7.60 (1H, d, J 8.6 Hz), 7.76 (1H, d, J 8.6 Hz), 8.14 (1H, d, 
J 8.6 Hz), 8.17 (1H, s), 8.44 (1H, d, J 8.6 Hz), and 8.57 (1H, s); δC (125 MHz; DMSO-d6) 119.5, 
119.7, 121.4, 122.3, 123.0, 126.6, 129.9, 130.6, 131.1, 132.8, 133.9, and 168.0; HRMS (FAB) m/z 
Calc. for C12H7N2O2 [M – H]– 211.0513, found 211.0523. 
 
Molecular modeling study of CK2 complexes with benzo[g]indazole 6a, 6f, and 6g 
 Complex structures of CK2 with 6a, 6f, and 6g were modeled manually based on the crystal 
structure of CK2 with 3a using MOE. Each model was subjected to energy minimization applying 
the MMFF force field, and then the binding affinity was estimated by the MM/GBVI method. 
 
CK2 kinase assay 
CK2 or CK2' kinase reaction was done in a reaction buffer [0.015 cm3; 20 mM MOPS pH 
7.2, 25 mM -glycerol phosphate, 5 mM EGTA, 1 mM sodium orthovanadate, 13.5 mM MgCl2, 0.4 
M PKA inhibitor cocktail, 0.2 mM CK2 substrate peptide (RRRDDDSDDD), 8.5 mU CK2 
enzyme, 90 M ATP, 2.2 nM [-32P] ATP]. After incubation at 37 °C for 10 min, the reaction was 
terminated by the addition of 0.010 cm3 of 40% TCA. 0.005 cm3 of the solution was transferred onto 
a 96-well P81 UniFilter (Whatman), and each well was washed with 0.20 cm3 of 0.75% phosphoric 
acid solution 20 times. Residual radioactivity was measured using TOP count NXT (PerkinElmer) 
after 30-min incubation in 0.020 cm3 of Microscinti-0 (PerkinElmer). 
 
Growth inhibition assay 
HCT-116 cells were cultured in McCoy’s 5A medium (GIBCO), supplemented with 10% (v/v) 
FBS at 37 °C in a 5% CO2 incubator. Growth inhibition assays using HCT-116 cells were performed 
in 96-well plates (BD Falcon). HCT-116 cells were seeded at 5000 cells/well in 0.050 cm3 of culture 
media and placed for 6 hr. Chemicals in DMSO were diluted 200-fold with the culture medium in 
advance. Following the addition of 0.040 cm3 of the fresh culture medium, 0.030 cm3 of the chemical 
diluents were also added to the cell cultures. The final volume of DMSO in the medium was equal to 
0.125% (v/v). The cells under chemical treatment were incubated for a further 72 hr. The wells in the 
plates were washed twice with Phenol-red minus medium [McCoy’s 5A medium (Thermo 
Scientific)]. After 1 hour incubation with 0.10 cm3 of the medium, the cell culture in each well was 
supplemented with 0.020 cm3 of the MTS reagent (Promega), followed by incubation for an 
additional 40 min. Absorbance at 490 nm of each well was measured using a Wallac 1420 ARVO SX 
multilabel counter (Perkin Elmer). 
 
Acknowledgements 
This work was supported by Fundamental Studies in Health Sciences of the National Institute of 
Biomedical Innovation (NIBIO), and Grants-in-Aid for Scientific Research and Platform for Drug 
Design, Discovery and Development from the MEXT, Japan. Y.S. and Z.H. are supported by a JSPS 
Research Fellowship for Young Scientists, and by the Kobayashi International Scholarship 
Foundation, respectively. 
 
References and notes 
1. J. S. Duncan and D. W. Litchfield, Biochim. Biophys. Acta, 2008, 1784, 33–47. 
2. (a) J. W. Critchfield, J. E. Coligan, T. M. Folks and S. T. Butera, Proc. Natl. Acad. Sci. U.S.A., 
1997, 94, 6110–6115; (b) H. L. Yim, Y. H. Lee, C. H. Lee and S. K. Lee, Planta Med., 1999, 65, 
9–13; (c) E. Vangrevelinghe, K. Zimmermann, J. Schoepfer, R. Portmann, D. Fabbro and P. 
Furet, J. Med. Chem., 2003, 46, 2656–2662; (d) Z. Nie, C. Perretta, P. Erickson, S. Margosiak, 
R. Almassy, J. Lu, A. Averill, K. M. Yager and S. Chu, Bioorg. Med. Chem. Lett., 2007, 17, 
4191–4195; (e) A. Chilin, R. Battistutta, A. Bortolato, G. Cozza, S. Zanatta, G. Poletto, M. 
Mazzorana, G. Zagotto, E. Uriarte, A. Guiotto, L. A. Pinna, F. Meggio and S. Moro, J. Med. 
Chem., 2008, 51, 752–759. 
3. F. J. Lozeman, D. W. Litchfield, C. Pienning, K. Takio, K. A. Walsh and E. D. Krebs, 
Biochemistry, 1990, 29, 8436–8447. 
4. (a) F. Pierre, P. C. Chua, S. E. O’Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, J. Michaux, 
J. Nagasawa, M. K. Schwaebe, E. Stefan, A. Vialettes, J. P. Whitten, K. T. Chen, L. Darjania, R. 
Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, K. 
Trent, W. G. Rice and D. M. Ryckman, J. Med. Chem., 2011, 54, 635–654; (b) R. Battistutta, G. 
Cozza, F. Pierre, E. Papinutto, G. Lolli, S. Sarno, S. E. O’Brien, A. Siddiqui-Jain, M. Haddach, 
K. Anderes, D. M. Ryckman, F. Meggio and L. A. Pinna, Biochemistry, 2011, 50, 8478–8488. 
5. (a) Y. Suzuki, J. Cluzeau, T. Hara, A. Hirasawa, G. Tsujimoto, S. Oishi, H. Ohno and N. Fujii, 
Arch. Pharm., 2008, 341, 554–561; for the initial report of pyrazine-based CK2 inhibitors, see: 
(b) N. Fuchi, Y. Iura, H. Kaneko, M. Yamada and Y. Sekitani, Jpn. Pat., 145786, 2007. 
6. (a) T. Nakaniwa, T. Kinoshita, Y. Sekiguchi, T. Tada, I. Nakanishi, K. Kitaura, Y. Suzuki, H. 
Ohno, A. Hirasawa and G. Tsujimoto, Acta Crystallogr. Sect. F, 2009, 65, 75–79; (b) T. 
Kinoshita, Y. Sekiguchi, H. Fukada, T. Nakaniwa, T. Tada, S. Nakamura, K. Kitaura, H. Ohno, 
Y. Suzuki, A. Hirasawa, I. Nakanishi and G. Tsujimoto, Mol. Cell. Biochem., 2011, 356, 
97–105. 
7. Z. Hou, I. Nakanishi, T. Kinoshita, M. Yasue, R. Misu, Y. Suzuki, S. Nakamura, T. Kure, H. 
Ohno, K. Murata, K. Kitaura, A. Hirasawa, G. Tsujimoto, S. Oishi and N. Fujii, J. Med. Chem., 
2012, 55, 2899–2903. 
8. Lopez et al. have determined the tautomeric structure of various pyrazoles and indazoles by 
13C NMR analysis, see: C. Lopez, R. M. Claramunt, A. Trofimenko and J. Elguero, Can. J. 
Chem., 1993, 71, 678–684. 
9. (a) Y. Suzuki, Y. Ohta, S. Oishi, N. Fujii and H. Ohno, J. Org. Chem., 2009, 74, 4246–4251; (b) 
Y. Suzuki, S. Naoe, S. Oishi, N. Fujii and H. Ohno, Org. Lett., 2012, 14, 326–329. 
10. J. C. Antilla, J. M. Baskin, T. E. Barder and S. L. Buchwald, J. Org. Chem., 2004, 69, 
5578–5587. 
11. T. Hundertmark, A. F. Littke, S. L. Buchwald and G. C. Fu, Org. Lett., 2000, 2, 1729–1731. 
12. A. A. Haddach, A. Kelleman and M. V. Deaton-Rewolinski, Tetrahedron Lett., 2002, 43, 
399–402. 
13. R. Joyeau, L. D. S. Yadav and M. Wakselman, J. Chem. Soc., Perkin Trans. 1, 1987, 
1899–1907. 
14. K. Knepper, S. Vanderheiden and S. Bräse, Eur. J. Org. Chem., 2006, 1886–1898. 
15. J. García-Fortanet, S. L. Buchwald, Angew. Chem., Int. Ed., 2008, 47, 8108–8111. 
16. T. Kawase, A. Konishi, Y. Hirao, K. Matsumoto, H. Kurata and T. Kubo, Chem. Eur. J., 2009, 
15, 2653–2661. 














3a: R = H





































































































Figure 3. (A) Pyrazine-based CK2 inhibitors 2 and dipyrrolo[3,2-b:2',3'-e]pyridines 5; (B) 
pyrazole-based CK2 inhibitor 4, benzo[g]indazoles 6, and their tautomers 4' and 6'; and (C) 
















11a–e: (R, R') = (Me or Et, Ms)
5a–e: (R, R') = (H, H)
8 : R = Ms











Scheme 1. Synthesis of dipyrrolo[3,2-b:2',3'-e]pyridine derivatives 5a–e. Reagents and conditions: 
(a) cat. CuI, Et3N, 1,4-dioxane, 60 °C, 5 min; (b) Cs2CO3, MeOH/THF, rt, 12 h; (c) cat. CuI/(±)-A, 







12: R = H


























17a: R1 = Ph
17b: R1 = C6H4(4-OMe)
17c: R1 = thiophen-2-yl
17d: R1 = n-Pr
21a– f: (X, Y) = (CO2Me, Me)
6a– f: (X, Y) = (H, H)
18
19a: R2 = H







Scheme 2. Synthesis of benzo[g]indazole derivatives 6a–f via three-component annulation and 
cyclization cascade. Reagents and conditions: (a) H2SO4, MeOH, reflux, 20 h; (b) NaNO2, HCl, H2O, 
0 °C, 1 h, then KI, rt, 24 h; (c) TMS-acetylene, cat. PdCl2(PPh3)2/CuI, Et3N, THF, rt, 1.5 h; (d) cat. 
PdCl2(PhCN)2/t-Bu3P/CuI, i-Pr2NH, toluene, rt; (e) K2CO3, MeOH, rt, 1 h; (f) cat. IPrAuCl/AgOTf, 
AcOH, 35–80 °C; (g) anisole, TFA, 80 °C (for 21a, 21b, 21d and 21f); (h) DDQ, CH2Cl2/H2O, rt (for 






















21g: (X, Y) = (Bn, Me)








Scheme 3. Synthesis of benzo[g]indazole derivative 6g. Reagents and conditions: (a) 85 °C, 8 h; (b) 
AcONa, AcOH, 60 °C, 5 h; (c) TMS-acetylene, cat. PdCl2(PPh3)2/CuI, Et3N, THF, rt, 4.5 h; (d) 
K2CO3, MeOH, rt, 1 h; (e) cat. IPrAuCl/AgNTf2, xylene, 130 °C; (f) t-BuOK, DMSO, THF/H2O, O2, 
rt, 0.5 h. 
 











compd HO2C-Ar- IC50 (M) compd R1 R2 IC50 (M) 
  CK2 CK2'     CK2 CK2'
5a 
HO2C











H 0.089 0.067 




i-Pr 5.97 7.56 
5d N
HO2C





H 0.040 0.042 
5e N
CO2H





i-Pr 3.36 2.52 
1 
(CX-4945) 
- 0.014 0.014 
 
6f n-Pr H 0.82 0.49 
4 - 0.14 0.063 
 
6g H H 2.2 1.0 
a Less than 20% inhibition was observed in the presence of 32 M of compounds. 
